Michael F. O’Neill

ORCID: 0000-0001-8253-4329
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Marine and fisheries research
  • Fish Ecology and Management Studies
  • Marine Bivalve and Aquaculture Studies
  • Cancer Mechanisms and Therapy
  • Neurotransmitter Receptor Influence on Behavior
  • Child and Adolescent Health
  • Neuroscience and Neuropharmacology Research
  • Receptor Mechanisms and Signaling
  • Fish Biology and Ecology Studies
  • Neuropeptides and Animal Physiology
  • Innovations in Medical Education
  • Neuroendocrine regulation and behavior
  • Ichthyology and Marine Biology
  • Healthcare Policy and Management
  • Emergency and Acute Care Studies
  • Coral and Marine Ecosystems Studies
  • Neurological disorders and treatments
  • Fish biology, ecology, and behavior
  • Crustacean biology and ecology
  • Healthcare Systems and Technology
  • Quinazolinone synthesis and applications
  • Lipoproteins and Cardiovascular Health
  • Clinical Reasoning and Diagnostic Skills
  • Zebrafish Biomedical Research Applications
  • Pharmacological Effects and Assays

Mayo General Hospital
2010-2025

Beaumont Hospital
2013-2025

Eli Lilly (United States)
1997-2025

Our Lady's Hospital
2023

Queen's University Belfast
2023

Mercy University Hospital
2021-2022

Royal College of Physicians of Ireland
2021

Public Health Scotland
2020

Emory University
2016

Department of Agriculture, Fisheries and Forestry
2012-2015

In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk events, but effects on mortality from overall have remained uncertain.In double-blind, randomized trial, we compared pravastatin (40 mg daily) those placebo over mean follow-up period 6.1 years in 9014 who were 31 to 75 age. The had history myocardial infarction or hospitalization for unstable angina initial plasma total levels 155 271 per deciliter. Both groups...

10.1056/nejm199811053391902 article EN New England Journal of Medicine 1998-11-05

10.1007/s12603-015-0589-6 article EN cc-by-nc-nd The journal of nutrition health & aging 2015-09-18

Purpose To develop low-dose thin-section computed tomographic (CT) protocols for assessment of cystic fibrosis (CF) in pediatric patients and determine the clinical usefulness thereof compared with chest radiography. Materials Methods After institutional review board approval informed consent from or guardians were obtained, 14 CF 11 without (16 male, nine female; mean age, 12.6 years ± 5.4 [standard deviation]; range, 3.5–25 years) who underwent imaging reasons CT. Sections 1 mm thick...

10.1148/radiol.10100278 article EN Radiology 2010-09-28

Bronchiectasis is an airway disease characterized by thickening of the bronchial wall, chronic inflammation , and destruction affected bronchi. Underlying etiologies include severe pulmonary infection cystic fibrosis (CF); however, in a substantial number patients with non-CF-related bronchiectasis (NCFB), no cause found. The increasing armamentarium therapies now available to combat CF stark contrast limited tools employed NCFB. Our study aimed evaluate similarities differences inflammatory...

10.2147/jir.s40081 article EN cc-by-nc Journal of Inflammation Research 2013-01-01

The mechanisms underlying the neuroprotective effects of group II metabotropic glutamate receptor (mGluR) agonist LY379268 were investigated in a gerbil model global ischemia. (10 mg/kg i.p.) 30 or 60 min after 5-min bilateral carotid artery occlusion (BCAO) attenuated ischemia-induced hyperactivity and provided protection CA1 hippocampal cells. This effect was maintained (P <.001) when histological analysis performed 14 28 days BCAO. Furthermore, 24- 48-h pretreatment with LY379268, 10...

10.1016/s0022-3565(24)39139-6 article EN Journal of Pharmacology and Experimental Therapeutics 2000-09-01

Objective This study aimed to evaluate the difficult intravenous access (DIVA) score, a clinical prediction rule, which states that children with score of 4 or more will have 50% higher rate failed placement on first attempt compared mean failure rate. Methods was prospective cohort in 0 14 years, undergoing peripheral by doctors emergency department medium-sized general hospital. Before attempts, demographic data inclusive age and DIVA were recorded. A maximum 3 attempts per doctor allowed,...

10.1097/pec.0b013e3182768bc9 article EN Pediatric Emergency Care 2012-11-27

Article16 July 2019Open Access Source DataTransparent process Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma Sofie Mohlin Corresponding Author [email protected] orcid.org/0000-0002-2458-3963 Division Pediatrics, Department Clinical Sciences, Lund University, Lund, Sweden Search for more papers by this author Karin Hansson Laboratory Medicine, Translational Cancer Research, University Center, Katarzyna Radke Sonia Martinez orcid.org/0000-0003-2230-7794...

10.15252/emmm.201810058 article EN cc-by EMBO Molecular Medicine 2019-07-16

Abstract The proviral integration of Moloney virus (PIM) family protein kinases are overexpressed in many haematological and solid tumours. PIM kinase expression is elevated PI3K inhibitor-treated breast cancer samples, suggesting a major resistance pathway for inhibitors cancer, potentially limiting their clinical utility. IBL-302 novel molecule that inhibits both PI3K/AKT/mTOR signalling. We thus evaluated the preclinical activity IBL-302, range models. Our results demonstrate vitro...

10.1038/s41388-020-1202-y article EN cc-by Oncogene 2020-02-10

ABSTRACT Provirus Integration site for Moloney leukemia virus (Pim) family members are well‐known oncogenes, with an expression that is restricted to few cell types including hematopoietic cells in adult organisms, making it a promising target lymphoma treatment. Indeed, previous studies mature T‐cell (mTCL) revealed frequent upregulation of Pim expression. Nevertheless, inhibition kinases showed only minor effects on the viability mTCL so far. Thus, we here addressed cellular responses...

10.1111/ejh.14420 article EN cc-by European Journal Of Haematology 2025-03-31

Abstract Background/Aims Treatment (tx) guidelines for PsA recommend biologic DMARDs (bDMARDs) or targeted synthetic (ts) after inadequate response to conventional (csDMARDs). In clinical studies, ixekizumab (IXE) has shown efficacy in patients (pts) with who were bDMARD-naive, TNFi-experienced, and without concomitant csDMARDs. Data from real-world studies are limited. This interim analysis reports the effectiveness of IXE other b/tsDMARDs b/tsDMARD-naive (naive) -experienced (exp) pts as...

10.1093/rheumatology/keaf142.203 article EN Lara D. Veeken 2025-04-01
Coming Soon ...